TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Ind Swift Laboratories Lt
INDSWFTLAB

Ind Swift Laboratories Lt Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 46/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹404.35

Change

+3.1 (0.77%)

Open

₹398.0

Prev. Close

₹401.25

Day High

₹410.0

Day Low

₹395.0

Volume Analysis

Traded

441,614

Delivered

149,646

Delivery %

33.89%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (2)

  • •Low return on equity (3.87%)
  • •Below-average fundamentals quality score (46/100)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹426.24 ₹418.12 ₹411.24 ₹403.12 ₹396.24 ₹388.12 ₹381.24
Fibonacci ₹418.12 ₹412.39 ₹408.85 ₹403.12 ₹397.39 ₹393.85 ₹388.12
Camarilla ₹408.48 ₹407.1 ₹405.73 ₹403.12 ₹402.98 ₹401.6 ₹400.23

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+346.84%

1 Week

+6.58%

1 Month

+11.42%

3 Months

+98.67%

6 Months

+192.65%

1 Year

+304.63%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹130.63

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

3.94%

Net margin 8.57% × asset turnover 0.38x × equity multiplier 1.21x

Company Overview

Sector

Healthcare

Market Cap

₹3,489 Cr

P/E (TTM)

53.6

ROE

3.87%

Book Value

₹159.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.

TopFund Analysis

Ind Swift Laboratories Lt scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 46/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (3.87%); below-average fundamentals quality score (46/100). FII holding has been rising.

TopFund Score — Fundamentals Quality

46/100 — Weak

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

0

Valuation

25

Cash Flow

0

Corporate Governance

66

Momentum

94

Institutional Ownership

39

Business Quality

42

Risk & Volatility

52

Liquidity

58

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company is expected to give good quarter
  • −Stock is trading at 2.52 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -6.37% over past five years.
  • −Company has a low return on equity of 6.11% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep

Schedule of Analyst / Investor Meet scheduled to be held on Tuesday, 29th September, 2026, at 01.00 P.M. IST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 22 Sep 22 Sep
Disclosures Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares And Takeover) Regulations, 2011 21 Sep

Essix Biosciences acquired 70 lakh warrants on 17 Sep 2026 via preferential issue.

Announcement under Regulation 30 (LODR)-Allotment 17 Sep

Allotted 70 lakh convertible warrants to promoter group at Rs 196 each, raising Rs 34.3 crore.

Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Sep 06 Sep

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 310 290 288 529 33 12 129 138 153 153 151 170 191
Expenses + 250 224 236 437 43 24 135 147 149 151 147 149 158
Operating Profit 60 66 52 91 -10 -12 -7 -9 4 1 4 21 33
OPM % 19.0% 23.0% 18.0% 17.0% -29.0% -99.0% -5.0% -7.0% 2.4% 1.0% 2.8% 12.0% 17.0%
Other Income + 6 7 7 458 11 13 16 220 15 18 22 -3 7
Interest 20 21 21 3 0 0 10 -27 1 2 1 -2 1
Depreciation 14 13 14 20 0 0 6 7 7 7 9 8 8
Profit before tax 32 39 24 527 1 1 -7 230 10 10 16 12 33
Tax % 45.0% 18.0% 19.0% 6.0% -3.0% 31.0% -16.0% 4.0% 17.0% 22.0% 42.0% -26.0% 25.0%
Net Profit + 17 32 19 494 1 0 -5 222 9 8 10 15 25
EPS in Rs 3 5 3 84 0 0 -1 37 1 1 1 2 3
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 660 653 716 765 757 780 891 1,039 1,207 1,281 562 641 665
Expenses + 571 546 610 631 630 635 709 837 978 1,029 581 596 605
Operating Profit 89 107 106 134 126 144 183 202 229 252 -19 45 60
OPM % 13.0% 16.0% 15.0% 18.0% 17.0% 19.0% 21.0% 19.0% 19.0% 20.0% -3.5% 7.0% 9.0%
Other Income + -31 1 15 16 120 33 23 37 7 434 305 36 44
Interest 117 106 88 28 92 107 100 96 92 51 3 1 1
Depreciation 84 85 88 87 104 90 87 131 57 53 24 31 32
Profit before tax -143 -83 -55 36 50 -20 18 13 87 582 258 49 71
Tax % -17.0% -29.0% -29.0% 39.0% 42.0% 7.0% 117.0% 117.0% 45.0% 28.0% 3.0% 16.0% —
Net Profit + -119 -59 -39 22 29 -21 -3 -2 48 421 250 41 57
EPS in Rs -29 -14 -9 5 6 -4 -1 0 8 71 41 5 7
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 553 476 486 507 540 581 544 541 622 872 1,104 1,297
Borrowings + 1,413 1,457 1,242 1,083 1,148 1,031 1,005 953 862 17 41 18
Other Liabilities + 236 240 364 387 188 198 210 247 280 217 224 271
Total Liabilities 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,165 1,438 1,673
Fixed Assets + 1,117 1,099 1,042 934 914 843 753 630 587 8 273 306
CWIP 113 78 70 69 20 11 19 10 8 0 0 10
Investments 18 18 18 18 19 17 36 29 30 111 213 248
Other Assets + 997 1,020 1,007 1,002 972 998 1,011 1,131 1,199 1,047 952 1,110
Total Assets 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,165 1,438 1,673
Equity Capital 42 42 45 46 48 60 60 60 60 59 69 87

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 98 79 96 73 -64 125 135 150 195 -163 -25 -70
Cash from Investing Activity + -35 -29 -31 -17 -12 -9 -10 5 -13 -104 -110 -73
Cash from Financing Activity + -64 -48 -69 -62 100 -133 -124 -141 -186 699 69 142
Net Cash Flow -1 3 -4 -6 23 -17 1 14 -4 431 -66 -1
CFO/OP 111 74 90 54 -51 87 73 74 85 -65 131 -140
Free Cash Flow 59 49 63 52 -79 114 131 137 182 -205 -51 -156

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 42.01% → 42.93%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 38.34% 38.96% 49.72% 55.81% 56.41% 56.61% 55.08% 53.88% 45.02% 45.5% 43.14% 46.19%
Promoters 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 40.94% 40.94% 39.49% 39.49% 43.0% 42.93%
FII 0.17% 0.31% 0.26% 1.27% 0.65% 0.46% 3.07% 4.27% 14.8% 14.33% 13.88% 10.7%
DII 19.49% 18.73% 8.03% 0.94% 0.94% 0.94% 0.91% 0.91% 0.68% 0.68% 0.0% 0.17%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ind Swift Laboratories Lt (this stock) 3,489 53.6 2.52 3.87%
Solara Active Pha Sci Ltd 3,587 840.0 2.14 -0.13%
Advanced Enzyme Tech Ltd 3,278 20.8 2.01 10.2%
Kwality Pharmaceuticals L 3,824 46.8 11.48 22.6%
Unichem Laboratories Ltd 3,870 31.7 1.42 3.17%
Aarti Drugs Ltd. 3,991 20.7 2.57 13.4%
Gufic Biosciences Ltd. 4,237 57.7 6.37 10.1%

Which Mutual Funds Hold Ind Swift Laboratories Lt?

Frequently Asked Questions about Ind Swift Laboratories Lt

Community Sentiment

What are other investors saying about Ind Swift Laboratories Lt?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.